key: cord-1000677-61heojxe
authors: Giménez, Estela; Albert, Eliseo; Burgos, Javier S.; Peiró, Salvador; Salas, Dolores; Vanaclocha, Hermelinda; Limón, Ramón; Alcaraz, María Jesús; Sánchez-Payá, José; Díez-Domingo, Javier; Comas, Iñaki; Gonzáles-Candelas, Fernando; Navarro, David
title: SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine
date: 2022-03-02
journal: J Infect
DOI: 10.1016/j.jinf.2022.02.035
sha: be5185609399b6235ba97238f4fd9b60d15e514a
doc_id: 1000677
cord_uid: 61heojxe

Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).

colleagues who reported a significant antibody decrease at around 6 months after full vaccination in healthcare workers, that was more marked in SARS-CoV-2 naïve vaccinees [1] . The authors suggested that in a supply-limited environment, booster dose schemes may be spared for SARS-CoV-2-experienced individuals. The data presented herein extend this observation to elderly nursing home residents. The current prospective cohort study included 680 (478 female; median age, 87 years; range 65-100) of a cohort of 881 nursing home residents initially recruited from a representative sample of Valencian Community nursing homes (n=13) for assessment of SARS-CoV-2 immune responses at a median of 3 months (3M) following full-dose Comirnaty® COVID-19 vaccination [2] who were re-examined at a median of 219 days (range, 139- Health of the Valencian Community), without requiring informed consent or ethics approval by an institutional review board. Likewise, in accordance with local law and regulations, data publication is exempt from the research ethics committee approval.

Personal data from nursing homes and residents were processed in accordance with European data protection regulations.

All participants were initially examined for presence SARS-CoV-2-Spike (S)-specific antibodies in whole blood obtained by fingerstick using a lateral flow immunochromatographic assay (LFIC): the OnSite COVID-19 IgG/IgM Rapid Test (CTK BIOTECH, Poway, CA, USA) [2] . As shown in Table 1 , a total of 148 of the 680 (21.7%) residents tested negative by LFIC at 7M. The percentage of residents without detectable anti-S LFIC responses at 7M was roughly double the proportion at 3M.

Moreover, overall, the strength of antibody reactivity [2] in LFIC among those who tested positive at both sampling times (n=520) tended to decrease by 7M: 169, 84 and 267 residents showed decreased, increased or similar antibody reactivity grades, respectively. Interestingly, SARS-CoV-2-experienced participants were more likely to display detectable and higher grade antibody responses at 7M than SARS-CoV-2-naïve participants ( Figure 1A ). Indeed, negative LFIC results were registered in 11/238 (95.8%) tested positive by RBD ECLIA and 108 (75%) by S-trimeric assay. Taking the above data together, 670/676 residents undergoing testing by LFIC and (E)CLIA (99.1%) exhibited detectable S-reactive antibody responses by 7M, a similar figure (98%) to that reported in the original cohort at 3M after vaccination [2] .

A total of 100 residents had 3M/7M paired plasma specimens analyzed by RBD ECLIA. As shown in Figure 1B , overall antibody levels declined over time, but particularly at the expense of SARS-CoV-2-naïve participants.

Participants testing negative for SARS-CoV-2 antibodies by all the above assays (n=6) with available specimens (n=5) were examined for presence of SARS-CoV-2-S-reactive IFNγ-producing T cells by whole-blood flow cytometry for intracellular cytokine staining (ICS), as previously described [2, 3] . Four residents had detectable S-targeted CD8 + T cells (median, 0.47%; range, 0.16-3.94%), whereas none had CD4 + T cells. We next examined 28 randomly selected participants (25 SARS-CoV-2-naïve and 3 experienced) testing negative by LFIC but positive by (E)CLIA: 23 displayed detectable CD8 + T-cell responses (median, 0.24%; range, 0.01-2.88%), 3 had both CD8 + and CD4 + T-cell (median, 0.44%; range, 0.03-0.77%) responses and 2 had neither.

Paired 3M/7M whole-blood specimens were available from 24 residents (Supplementary Table 1 ). Examining SARS-CoV-2-S-reactive IFNγ-producing CD8 + T cells, we observed that 8 residents who had not detectable responses at 3M acquired them by 7M, whereas 16 had documented responses at 3M, which were maintained in 14 and lost in 2. Regarding SARS-CoV-2-S-reactive IFNγ-producing-CD4 + T cells, most responders at 3M (21/22) no longer had detectable responses at 7M, whereas 1 out of 2 residents acquired them by 7M. Figure 1C illustrates that while SARS-CoV-2-Sreactive IFNγ-producing CD8 + T-cell levels increased slightly over time (P=0.12), those of CD4 + T cells declined dramatically (P<0.001). That most residents maintained detectable S-targeted CD8 + T-cell responses at 7M was in contrast to previously published data [4] reporting positive SARS-CoV-2 T-cell responses as determined by the QuantiFERON assay in only 5% of SARS-CoV-2-naïve participants at 24 weeks after full vaccination with the Comirnaty® vaccine. Nevertheless, it is uncertain how SARS-CoV-2 QuantiFERON assay and our flow cytometry ICS method compare analytically.

Limitations of the current study included the use of a semi-quantitative LFIC for frontline antibody testing and that functional specificities of SARS-CoV-2-S-reactive T cells beyond IFN-γ production were not explored.

In conclusion, our data indicated that both antibody and peripheral blood CD4 + T-cell levels measured after Comirnaty® vaccination in elderly nursing home residents wane over time in line with previous findings [2] [3] [4] [5] [6] [7] [8] , declining significantly by 7M after vaccination, particularly in SARS-CoV-2 naïve individuals. The IgG line intensity was scored visually using a 4-level scale, as previously reported [3] : 0 = negative result; 1+ = intensity of test band lower than control band; 2+= intensity of test band equal to control line; 3+ = intensity of test band greater than control line. Reactivities ≥2 in the LFIC assay corresponded roughly to antibody levels ≥250 IU/ml as measured by Elecsys® Anti-SARS-CoV-2 S-total antibody assay (Roche Diagnostics, Pleasanton, CA, USA). 

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

Immunological response against SARS-CoV-2 following full-dose administration of

Comirnaty COVID-19 vaccine in nursing home residents

B and T cell B and T cell immune responses elicited by the Comirnaty COVID-19 vaccine in nursinghome residents

Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study

Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty® COVID-19 vaccine

Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody

Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain